Easy, Accurate and Affordable Cancer Screening....Welcome to the Beacon Revolution!
The Power of Three
BeScreened™-CRC is an ELISA-based multiplex, screening test of three blood-based tumor-associated protein biomarkers; an oncoprotein called teratocarcinoma derived growth factor-1 (TDGF-1, Cripto-1); carcinoembryonic antigen (CEA), a well-established biomarker associated with CRC; and an extracellular matrix protein involved in early stage tumor stroma changes. These three proteins target immunological activities associated with CRC tumorigenesis; generation, invasion, progression, and migration.
The assay results are processed through Beacon’s proprietary relational algorithm and evaluated against the algorithm’s healthy patient-state status criteria. Patients that fall within the acceptance criteria are reported as negative for the likely presence of CRC with a recommendation to stay compliant with their individual healthcare well-checks and screening needs. Patients calculated as outliers to that same criteria are reported as positive with an elevated-risk of CRC’s presence with a recommendation to follow-up with their physician to schedule a screening colonoscopy.
BeScreened™-CRC is the solution to CRC screening noncompliance and was designed specifically for for this reason. It’s an easy, accurate and affordable blood-based test for CRC screening that can help increase screening compliance in the population of individuals who have been unwilling or unable to be screened using fecal-based testing or invasive imaging procedures, such as colonoscopies. In providing these individuals with another alternative test that is much easier to adopt and more convenient, we can help save more lives and assist in reducing the staggering costs associated with later stage colorectal cancer (CRC) treatment and care by increasing CRC screening compliance using BeScreened-CRC.
Our test is recognized by the FDA and Centers for Medic are and Medicaid Services as a CLIA laboratory developed test. As such, it is only available from through Beacon Biomedical Inc.'s CLIA accredited laboratory (ID 03D2122615). Practitioners interested in providing BeScreened-CRC to your screening non-compliant patients, please contact Beacon for more details and to check on its availability in your area.
Ease & Convenience
To provide additional ease and convenience for both practitioners and patients alike, Beacon has contracted with Sonora Quest Laboratories to provide for sample collection and processing across the entire state of Arizona through their network of patient service centers and physician based in-office phlebotomists. Patients and doctors can download a BeScreened Test Requisition Form Test by clicking "here" and take it to any SQL PSC to get their blood drawn. Click "here" for a list of SQL PSCs near you.SQL processes the samples and then they are delivered directly to Beacon for testing and reporting.
Colorectal cancer (CRC) is one of the most curable diseases with a 90% survivability rate when detected in its earlier stages. Yet, in the U.S. alone there are still more than 50,000 men and women dying each year from this devastating disease.
The data tells us that almost 65% of all CRC deaths and over 70% of all the associated cancer treatment and care costs can be directly attributable to the 30-million men and women who are CRC screening-eligible but simply don’t get screened. Surprisingly, over 70% of these very same individuals are fully covered by insurance, and over 90% of them have regular visits to their physicians and have blood drawn for well-check purposes.
Patients who are not compliant with their CRC screening say they don’t participate in screening because they find the current fecal-based tests and colonoscopy procedures disgusting, painful, embarrassing or simply inconvenient.
Wouldn’t it be great if there was a simple blood test that would screen for colorectal cancer (CRC)? A test that was as easy as getting checked for your cholesterol?
Well, now there is and it’s called “BeScreened™-CRC”.
Beacon Biomedical has developed a simple blood-based CLIA laboratory developed test (LDT) for CRC screening specifically intended for those individuals who have been, and continue to be,UNWILLING or UNABLE to participate in screening using current recommended fecal-based tests an invasive imaging procedures, such as colonoscopy. BeScreened-CRC is 94.6% accurate at determining a patient’s risk of having CRC,